The phase 2 type 2 diabetes trial evaluated maintenance doses including 0.5 mg, 4 mg, 8 mg, and 12 mg, with several escalation designs [5]
23 : 18831883 Pisano C, Camerini B, Castorina M, Olivi A, Ambrosini A, Calvani M
The rebound effect upon GLP-1R agonists withdrawal needs to be investigated further, and new drug developments should aim to mitigate this big limitation and find ways in which GLP-1R agonists could be used as short-term therapies without causing weight regain and cardiometabolic risk reversal
Always consult your provider before starting treatment
Verma S, Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Ronnback C, Abildstrom SZ, Liisberg K, et al